<DOC>
	<DOCNO>NCT00105456</DOCNO>
	<brief_summary>This prospective observational cohort study design describe effectiveness safety ( treatment outcomes clinically significant cardiac adverse event , respectively ) patient HER2-positive metastatic breast cancer .</brief_summary>
	<brief_title>A Study Patients With HER2-Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Signed Informed Consent document ( unless IRB grant waiver consent ) Signed Authorization Use Disclosure Health Information document HER2positive breast cancer Initial diagnosis metastatic ( Stage IV ) breast cancer within 6 month prior enrollment Availability cancerspecific historical data point patient 's medical record There exclusion criterion participation trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>HER2-Positive Metastatic Breast Cancer</keyword>
	<keyword>HER2</keyword>
</DOC>